Wen Jiang, M.D. Ph.D., earned his Ph.D. in biomedical engineering from the University of Toronto, where his research focused on developing nanomedicine for cancer diagnostic and therapeutic applications. After graduation, Dr. Jiang was awarded the prestigious Natural Science and Engineering Research Council of Canada (NSERC) Postdoctoral Fellowship and went on to conduct research at Massachusetts General Hospital and Harvard Medical School on how pathophysiological features of the tumor microenvironment restrict anti-cancer drug delivery.

After finishing his research fellowship, Dr. Jiang went on to obtain his medical degree from Stanford School of Medicine. During this time, he joined the laboratory of Dr. Irving Weissman as a Frederick Banting Research Fellow, where he studied how the bone marrow stromal microenvironment regulates hematopoietic stem cell development. Dr. Jiang’s hypothesis at that time, which was later proven to be true, was that during tumorigenesis, cancer cells share many of the cellular and molecular processes that govern normal stem-cell maintenance.

After graduating from medical school, Dr. Jiang entered the Radiation Oncology Residency Program at The University of Texas MD Anderson Cancer Center, where he continued to conduct leading-edge research as a resident, integrating his expertise in nanoengineering, tumor biology and tumor immunology research. For his research accomplishments, Dr. Jiang was awarded the Roentgen Resident Research Award and the Resident Research Grant from the Radiological Society of North America (RSNA), the Young Investigator Award from the American Society of Clinical Oncology (ASCO)/Conquer Cancer Foundation (CCF), the Susan Papizan Dolan Fellowship in Breast Oncology, and the Young Alumni Achievement Award from his alma mater, Carleton University.


Medical School
Stanford University School of Medicine (2013)
Santa Clara Valley Medical Center (2014), Transitional Year
M.D. Anderson Cancer Center (2018), Radiation Oncology

Research Interest

  • Cancer immunotherapy
  • Cancer nanomedicine
  • Immunoengineering
  • Phagocytosis checkpoints
  • Tumor immunology


Featured Publications LegendFeatured Publications

NCR- group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development.
Liu Y, Song Y, Lin D, Lei L, Mei Y, Jin Z, Gong H, Zhu Y, Hu B, Zhang Y, Zhao L, Teo HY, Qiu J, Jiang W, Dong C, Wu D, Huang Y, Liu H, EBioMedicine 2019 Mar 41 333-344
The reciprocity between radiotherapy and cancer immunotherapy.
Wang Y, Liu Z, Yuan H, Deng W, Li J, Huang Y, Kim BYS, Story MD, Jiang W Clin. Cancer Res. 2018 Nov
The reciprocity cancer immunotherapy and radiotherapy
Wang Y, Liu ZG, Huang YH, Li J, Kim BYS, Story MD, Jiang W Clinical Cancer Research 2018
Immune modulating nanomedicine for cancer therapy
Liu Z, Jiang W (co-first author), Nam J, Moon JJ, Kim BYS Nano Letters 2018 18 6655-6659
Mutant LKB1 confers enhanced radiosensitization in combination with trametinib in KRAS-mutant non-small cell lung cancer
Wang Y, Li N, Jiang W, Deng W, Ye R, Xu C, Qiao Y, Sharma A, Zhang M, Hung MC, Lin SH Clinical Cancer Research 2018 24 22 5744-5756
Efficacy and toxic effects of cancer immunotherapy combinations: a double-edged sword
Tang C, Jiang W, Yap TA JAMA Oncology 2018 4 8 1116-1117

Honors & Awards

  • NCI Mentored Clinical Scientist Career Development Award
  • ASCO Young Investigator Award
  • RSNA Roentgen Award
  • RSNA Resident Research Grant
  • Carleton University Young Alumni Achievement Award

Professional Associations/Affiliations

  • American Society of Clinical Oncology (ASCO) (2016)
  • Society for Neuro-Oncology (SNO) (2016)
  • American Association for Cancer Research (AACR) (2014)
  • American Society for Radiation Oncology (ASTRO) (2014)